Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Ropivacaine Levels with Different Paravertebral Injection Sites
jRCT1031240233Active, not recruiting
- Sponsor
- Nihon University Itabashi Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ropivacaine in Spontaneous pneumothorax (SP) and bronchial carcinoma (2 arms), sponsored by Nihon University Itabashi Hospital. Primary endpoints: Maximum plasma concentration of ropivacaine (Cmax) and Time to reach maximum plasma concentration (Tmax). Started Aug 2024; status: active, not recruiting.
02
Drugs
ropivacaine
03
Conditions
Spontaneous pneumothorax (SP)bronchial carcinoma
Beyond the preview
Go deeper on jRCT1031240233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240233.